Antiretroviral drug resistance testing

Journal of Postgraduate Medicine

Volumn 52, Issue 3, 2006, Pages 187-193

  Sen, Sourav ^a   Tripathy, S ^a   Paranjape, R ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

Author keywords

Human immune deficiency virus type 1; Viral drug resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GAG PROTEIN; INDINAVIR; LAMIVUDINE; LOPINAVIR; LUCIFERASE; NELFINAVIR; PROTEINASE INHIBITOR; RIBONUCLEASE H; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; TENOFOVIR; THYMIDINE DERIVATIVE; ZALCITABINE;

ALGORITHM; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONFERENCE PAPER; CROSS RESISTANCE; DRUG TREATMENT FAILURE; GENOTYPE; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHENOTYPE; PRACTICE GUIDELINE; RELIABILITY; VIRUS GENOME; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE;

EID: 33746642501     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Coffin JM. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-9.
2. Mansky LM. Retrovirus mutation rates and their role in genetic variation. J Gen Virol 1998;79:1337-45.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
4. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
5. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988;242:1171-3.
6. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988;242:1168-71.
7. Rhodes T, Wargo H, Hu WS. High rates of human immunodeficiency virus type 1 recombination: Near-random segregation of markers one kilobase apart in one round of viral replication. J Virol 2003;77:11193-200.
8. Rhodes TD, Nikolaitchik O, Chen J, Powell D, Hu WS. Genetic recombination of human immunodeficiency virus type 1 in one round of viral replication: Effects of genetic distance, target cells, accessory genes and lack of high negative interference in crossover events. J Virol 2005;79:1666-77.
9. Kellam P, Larder BA. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol 1995;69:669-74.
10. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-28.
11. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retrov 1998;14:869-76.
12. Vahey M, Nau ME, Barrick S, Cooley JD, Sawyer R, Sleeker AA, et al. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol 1999;37:2533-7.
13. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Martinez-Picado J, Sutton L, et al. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 2000;38:2715-21.
14. Wilson JW, Bean P, Robins T, Graziano F, Persing DH. Comparative evaluation of three human immunodeficiency virus genotyping systems: The HIV-GenotypR method, the HIV PRT GeneChip assay and the HIV-1 RT line probe assay. J Clin Microbiol 2000;38:3022-8.
15. Servais J, Lambert C, Fontaine E, Plesseria JM, Robert I, Arendt V, et al. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol 2001;39:454-9.
16. Puchhammer-Stockl E, Schmied B, Mandl CW, Vetter N, Heinz FX. Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance. J Med Virol 1999;57:283-9.
17. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med 2005;13:51-7.
18. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 2001;15:309-20.
19. Hoefnagel JG, Koopmans PP, Burger DM, Schuurman R, Galama JM. Role of the inhibitory quotient in HIV therapy. Antivir Ther 2005;10:879-92.
20. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, et al. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001;39:1522-9.
21. Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001;98:13907-12.
22. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the Drug Resistance Mutations in HIV-1: Fall 2005. Top HIV Med 2005;13:125-31.
23. Ross L, Parkin N, Chappey C, Fisher R, Clair MS, Bates M, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004;18:1691-6.
24. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003;77:1512-23.
25. Torti C, Quiros-Roldan E, Monno L, Patroni A, Saracino A, Angarano G, et al. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. J Med Virol 2004;74:29-33.
26. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance. AIDS 2003;17:955-61.
27. Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, et al. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: Effect on response to efavirenz-based therapy in an urban observational cohort. J Infect Dis 2004;189:1688-95.
28. Mo H, King MS, King K, Molla A, Brun S, Kempf DJ. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005;79:3329-38.
29. Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up. Antivir Ther 2000;5:65-70.
30. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-93.
31. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16:369-79.
32. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002;16:209-18.
33. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002;16:579-88.
34. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005;19:295-302.
35. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-36.
36. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: Results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004;38:723-30.
37. Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, et al. A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: Evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr 2005;38:553-9.
38. Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003;32:268-80.
39. Perez-Elias MJ, Garcia-Arota I, Munoz V, Santos I, Sanz J, Abraira V, et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study. Antivir Ther 2003;8:577-84.
40. Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, et al. A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted Regimens (RADAR) Study. Clin Infect Dis 2005;40:1828-36.
41. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.hivatis.org. Accessed 06 Nov 2005.
42. World Health Organisation. Guidelines for surveillance of HIV drug resistance. 2003. Available at: http://www.phppo.cdc.gov/dls/ila/cd/who-afro/ resisguide12_12.pdf. Accessed 06 Nov 2005
43. Kuritzkes D. Making sense of resistance testing. HIV/AIDS: Annual Update 2001. Available at: http://www.medscape.com. Accessed on 10 Oct 2005
44. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005;38:37-42.
45. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003;41:4531-6.
46. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis. J Clin Microbiol 2005;43:406-13.
47. Metzner KJ, Rauch P, Walter H, Boesecke C, Zollner B, Jessen H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005;19:1819-25.
48. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, et al. LigAmp for sensitive detection of single-nucleotide differences. Nat Met 2004;1:141-7.
49. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012. J Infect Dis 2005;192:24-9.
50. Dunn DT, Gibb DM, Babiker AG, Green H, Darbyshire JH, Weller IV. HIV drug resistance testing: is the evidence really there? Antivir Ther 2004;9:641-8.
51. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003;37:1693-8.
52. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-41.
53. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Eng J Med 2002;347:385-94.
54. Garcia-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-93.
55. Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, et al. Tenofovir Resistance and Resensitization. Antimicrob Agents Chemother 2003;47:3478-84.
56. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-8.
57. Shafer RW. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin Microbiol Rev 2002;15:247-77.
58. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. JAMA 2000;283:2417-26.
59. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005;192:16-23.
60. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20:159-70.
61. Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H. Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise Compromised Replication of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors. J Virol 2004;78:12030-40.
62. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006;80:750-8.
63. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci 2005;102:2093-8.